SCHEMBL6043780

SCHEMBL6043780

CC(C)(C)OC(=O)N1CCC(c2cccnc2)C(O)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.56
JAK2 O60674 1/20 0.46
JAK3 P52333 1/20 0.46
PTK2 Q05397 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
HIF1A Q16665 1/20 0.46
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
USP30 Q70CQ3 2/20 0.44
CCNK O75909 1/20 0.44
CDK12 Q9NYV4 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
TACR1 P25103 1/20 0.43
KDM1A O60341 1/20 0.42
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16272063 0.90 GPR119 (0.57) GPR119KDM4EMEN1ALDH1A1MAPT
SCHEMBL2246047 0.86 GPR119 (0.54) GPR119JAK2JAK3PTK2KDM4E
SCHEMBL2242108 0.86 GPR119 (0.54) GPR119JAK2JAK3PTK2KDM4E
SCHEMBL407256 0.86 GPR119 (0.54) GPR119JAK2JAK3PTK2KDM4E
SCHEMBL14497248 0.85 GPR119 (0.60) GPR119MAPTCCNKCDK12NAMPT
SCHEMBL30417389 0.85 GPR119 (0.60) GPR119MAPTCCNKCDK12NAMPT
SCHEMBL6956572 0.82 GPR119 (0.42) GPR119KDM4EMEN1ALDH1A1MAPT
SCHEMBL3154994 0.82 GPR119 (0.65) GPR119KDM4EMAPTCCNA2CDK2
SCHEMBL8183234 0.82 HSD11B1 (0.44) KDM4EMEN1ALDH1A1KMT2ANAMPT
SCHEMBL25274630 0.81 GPR119 (0.56) GPR119KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 GPR119 856/4885JAK2 4667/4885JAK3 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.